Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Measles, Mumps, and Rubella Virus Vaccine Live · 1 trial · 1 indication
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Group 3 data were presented separately.
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay.
| Arm | Type | Description |
|---|---|---|
| Group 1: MenACYW Conjugate Vaccine (Mexico) | EXPERIMENTAL | Participants aged 2 months (at the time of enrollment) received Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus toxoid (MenACYW) Conjugate vaccine at the age of Months 2, 6, and 12 along with Prevnar 13®, Hexacima®, vaccines at the age of Months 2, 4, 6 and 12; RotaTeq® vaccine at the age of Months 2, 4 and 6 and measles, mumps, rubella (MMR®II) vaccine at the age of Month 12. |
| Group 2: Menveo® (Mexico) | ACTIVE_COMPARATOR | Participants aged 2 months (at the time of enrollment) received Menveo® vaccine at the age of Months 2, 4, 6, and 12 along with Prevnar 13®, Hexacima® vaccines at the age of Months 2, 4, 6 and 12; RotaTeq® vaccine at the age of Months 2, 4 and 6, and MMR®II vaccine at the age of Month 12. |
| Group 3: MenACYW Conjugate Vaccine (Russian Federation) | EXPERIMENTAL | Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 3, 6, and 12 along with Prevnar 13® vaccine at the age of Months 2, and 4.5; Pentaxim® vaccine at the age of Months 3, 4.5, and 6; ENGERIX-B® vaccine at the age of Month 6 and MMR vaccine at the age of Month 12. |
| Group 4: Routine Pediatric Vaccines (Russian Federation) | OTHER | Participants aged 2 months (at the time of enrollment) received Prevnar 13® vaccine at the age of Months 2, and 4.5; Pentaxim® vaccine at the age of Months 3, 4.5, and 6; ENGERIX-B® vaccine at the age of Month 6 and MMR vaccine at the age of Month 12. |
| Name | Type | Description |
|---|---|---|
| Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | BIOLOGICAL | Pharmaceutical form: Liquid solution Route of administration : Intramuscular |
| Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine | BIOLOGICAL | Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular |
| Measles, Mumps, and Rubella Virus Vaccine Live | BIOLOGICAL | Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous |
| Pneumococcal 13-valent Conjugate Vaccine | BIOLOGICAL | Pharmaceutical form: Suspension for injection Route of administration: Intramuscular |
| Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine | BIOLOGICAL | Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular |
| Hepatitis B Vaccine | BIOLOGICAL | Pharmaceutical form: Suspension for injection Route of administration: Intramuscular |
| Rotavirus Vaccine, Live, Pentavalent | BIOLOGICAL | Pharmaceutical form: Oral solution Route of administration: Oral |
| Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine | BIOLOGICAL | Pharmaceutical form:Suspension for injection Route of administration: Intramuscular |
Inclusion criteria: An individual must fulfill all of the following criteria in order to be eligible for trial enrollment: * Infants 2 months of age (60 to 89 days of age) on the day of the first study visit.\* * Born after a full-term pregnancy, with an estimated gestation age \>= 37 weeks and a ...
Measles, Mumps, Rubella and Varicella is a vaccine being studied for use in healthy volunteers and for meningococcal meningitis. It is a combination vaccine that includes components for measles, mumps, rubella, and varicella, and is being evaluated in clinical trials for its immunogenicity and safety.
Sanofi (ticker: SNY) is the developer of Measles, Mumps, Rubella and Varicella. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in pediatric populations.
Measles, Mumps, Rubella and Varicella is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 3 trials are completed, with one trial enrolling 1,664 participants and another enrolling 525 participants.
Measles, Mumps, Rubella and Varicella has been studied in two Phase 3 trials. NCT00422292 evaluated the vaccine's immunogenicity and safety when administered with Menactra in healthy toddlers in the United States and Puerto Rico. NCT03630705 assessed a quadrivalent meningococcal conjugate vaccine given with routine pediatric vaccines in healthy infants and toddlers in Russia and Mexico.
Yes, Measles, Mumps, Rubella and Varicella is also known as Measles, combinations with mumps and rubella, live attenuated. This alternative name reflects the vaccine's composition, which includes live attenuated components for measles, mumps, and rubella, along with varicella.